Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Korro Bio, Inc.NASDAQ: KRRO
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns positive
Q1 FY2026 other non-cash items was $242K, compared with -$182K a year earlier. Trailing-twelve-month other non-cash items was $35.13M. Over 3 fiscal years it compounded at +175.6% a year.
Context
- Other non-cash items amounted to 495.6% of revenue in FY2025, up 412.4 pp from a year earlier.
- Other non-cash items increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near $242K or moves back toward the trailing-twelve-month quarterly average of $8.78M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 31.68M USD
- Year-over-year change
- +1577.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.68M | +1577.0% |
| FY2024 | 2024-12-31 | 1.89M | -47.5% |
| FY2023 | 2023-12-31 | 3.6M | +137.5% |
| FY2022 | 2022-12-31 | 1.51M | +111.3% |
| FY2021 | 2021-12-31 | (13.44M) | — |
Other Non-Cash Items vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 other non-cash items of $35.13M is the 2nd largest of the 11 companies compared; the peer median is $1.13M.
- Its year-over-year change of +6869.2% is the highest of 9, against a peer median of -6.8%.
- Other non-cash items amounts to 914.2% of revenue for KRRO, versus a peer median of 6886.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.22M | — | — | 7620.1% | |
| LTM Mar 2026 | $35.13M | +6869.2% | +175.6% | 914.2% | |
| LTM Mar 2026 | $22.77M | -431.8% | — | 10.6% | |
| LTM Mar 2026 | $13.99M | +178.1% | +521.5% | — | |
| LTM Mar 2026 | $4.01M | +59.1% | +61.6% | — | |
| LTM Mar 2026 | $2.48M | +254.0% | +43.3% | 6886.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $2.01M | — | -33.1% | — |
| LTM Mar 2026 | $1.33M | -72.8% | -30.0% | — | |
| LTM Mar 2026 | $1.21M | -85.6% | — | — | |
| LTM Mar 2026 | $252K | +111.8% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $7K | -99.4% | — | — |
| Peer median (excluding KRRO) | $1.13M | -6.8% | +43.3% | 6886.1% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.96M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Depreciation & Amortization | 1.6M | 2.51M | 3.63M | 3.57M | 3.79M |
| Deferred Income Tax | 0 | (145K) | 0 | 0 | 0 |
| Stock-Based Compensation | 807K | 1.14M | 2.38M | 4.46M | 7.66M |
| Change in Working Capital | 904K | (633K) | 4.28M | 13.59M | (4.43M) |
| Accounts Receivables | 0 | 0 | 0 | (1.7M) | 727K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 56K | 1.76M | 3.1M | (1.34M) | (2.31M) |
| Other Working Capital | 848K | (2.39M) | 1.18M | 16.63M | (2.84M) |
| Other Non-Cash Items | (13.44M) | 1.51M | 3.6M | 1.89M | 31.68M |
| Operating Cash Flow | (32.09M) | (53.65M) | (67.28M) | (60.07M) | (78.56M) |
| Capital Expenditures | (4.45M) | (5.21M) | (7.84M) | (17.9M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.07M) | (37.21M) | 0 | (146.35M) | (26.19M) |
| Sales of Investments | 0 | 53.49M | 19M | 40.9M | 70.7M |
| Other Investing Activities | 13K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (39.5M) | 11.06M | 11.16M | (123.35M) | 43.99M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28K | 62K | 117.25M | 67.39M | 685K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | (44K) | 25.05M | 1.97M | 0 |
| Financing Cash Flow | 115.95M | 18K | 187.76M | 69.36M | 685K |
| Effect of Forex Changes | 0 | 0 | 0 | (4K) | 64K |
| Net Change in Cash | 44.35M | (42.57M) | 131.64M | (114.07M) | (33.82M) |
| Free Cash Flow | (36.54M) | (58.86M) | (75.12M) | (77.98M) | (79.08M) |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.